期刊文献+

Clinical implications of hepatitis B virus mutations:Recent advances 被引量:12

Clinical implications of hepatitis B virus mutations:Recent advances
下载PDF
导出
摘要 Hepatitis B virus(HBV)infection is a major cause of acute and chronic hepatitis,and of its long-term complications.It is the most variable among DNA viruses,mostly because of its unique life cycle which includes the activity of error-prone enzyme,reverse transcriptase,and the very high virion production per day.In last two decades,numerous research studies have shown that the speed of disease progression,reliability of diagnostic methods and the success of antiviral therapy and immunization are all influenced by genetic variability of this virus.It was shown that mutations in specific regions of HBV genome could be responsible for unwanted clinical outcomes or evasion of detection by diagnostic tools,thus making the monitoring for these mutations a necessity in proper evaluation of patients.The success of the vaccination programs has now been challenged by the discovery of mutant viruses showing amino acid substitutions in hepatitis B surface antigen(HBsAg),which may lead to evasion of vaccine-induced immunity.However,the emergence of these mutations has not yet raised concern since it was shown that they develop slowly.Investigations of HBV genetic variability and clinical implications of specific mutations have resulted in significant advances over the past decade,particularly in regard to management of resistance to antiviral drugs.In the era of drugs with high genetic barrier for resistance,on-going monitoring for possible resistance is still essential since prolonged therapy is often necessary.Understanding the frequencies and clinical implications of viral mutations may contribute to improvement of diagnostic procedures,more proper planning of immunization programs and creating the most efficient therapeutic protocols. Hepatitis B virus (HBV) infection is a major cause of acute and chronic hepatitis, and of its long-term complications. It is the most variable among DNA viruses, mostly because of its unique life cycle which includes the activity of error-prone enzyme, reverse transcriptase, and the very high virion production per day. In last two decades, numerous research studies have shown that the speed of disease progression, reliability of diagnostic methods and the success of antiviral therapy and immunization are all influenced by genetic variability of this virus. It was shown that mutations in specific regions of HBV genome could be responsible for unwanted clinical outcomes or evasion of detection by diagnostic tools, thus making the monitoring for these mutations a necessity in proper evaluation of patients. The success of the vaccination programs has now been challenged by the discovery of mutant viruses showing amino acid substitutions in hepatitis B surface antigen (HBsAg), which may lead to evasion of vaccine-induced immunity. However, the emergence of these mutations has not yet raised concern since it was shown that they develop slowly. Investigations of HBV genetic variability and clinical implications of specific mutations have resulted in significant advances over the past decade, particularly in regard to management of resistance to antiviral drugs. In the era of drugs with high genetic barrier for resistance, on-going monitoring for possible resistance is still essential since prolonged therapy is often necessary. Understanding the frequencies and clinical implications of viral mutations may contribute to improvement of diagnostic procedures, more proper planning of immunization programs and creating the most efficient therapeutic protocols.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第24期7653-7664,共12页 世界胃肠病学杂志(英文版)
基金 Supported by Ministry of Education,Science and Technological Development,Republic of Serbia,Grant No.175073
关键词 HEPATITIS B VIRUS HEPATITIS B VIRUS VARIABILITY MU Hepatitis B virus Hepatitis B virus variability Mutation Drug resistance Vaccine escape
  • 相关文献

参考文献10

  • 1Chao-Hung Hung,Chien-Hung Chen,Sheng-Nan Lu,Jing-Houng Wang,Tsung-Hui Hu,Chao-Min Huang,Ming-Chao Tsai,Chuan-Mo Lee.Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy[J].Antiviral Research.2011(1)
  • 2Si-Jia Chen,Ying-Xin Zhao,Yong Fang,Wei-Zhen Xu,Yan-Xiu Ma,Zhi-Wei Song,Xu Teng,Hong-Xi Gu.Viral deletions among healthy young Chinese adults with occult hepatitis B virus infection[J].Virus Research.2011(1)
  • 3Fabien Zoulim,Stephen Locarnini.Hepatitis B Virus Resistance to Nucleos(t)ide Analogues[J].Gastroenterology.2009(5)
  • 4Yun–Fan Liaw,Edward Gane,Nancy Leung,Stefan Zeuzem,Yuming Wang,Ching Lung Lai,E. Jenny Heathcote,Michael Manns,Natalie Bzowej,Junqi Niu,Steven–Huy Han,Seong Gyu Hwang,Yilmaz Cakaloglu,Myron J. Tong,George Papatheodoridis,Yagang Chen,Nathaniel A. Brown,Efsevia Albanis,Karin Galil,Nikolai V. Naoumov.2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B[J].Gastroenterology.2009(2)
  • 5Jun Inoue,Yoshiyuki Ueno,Futoshi Nagasaki,Yuta Wakui,Yasuteru Kondo,Koji Fukushima,Hirofumi Niitsuma,Tooru Shimosegawa.Enhanced intracellular retention of a hepatitis B virus strain associated with fulminant hepatitis[J].Virology.2009(2)
  • 6Ding-Shinn Chen.Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B[J].Journal of Hepatology.2009(4)
  • 7ClaudioVelati,LuisaRomanò,LauraFomiatti,LorellaBaruffi,Alessandro RemoZanetti.Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey[J].Transfusion.2008(10)
  • 8CHAU‐TINGYEH,CHIA‐MINGCHU,YUN‐FANLIAW.Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C[J].Journal of Gastroenterology and Hepatology.2008(2)
  • 9George V Papatheodoridis,Spilios Manolakopoulos,Geoffrey Dusheiko,Athanasios J Archimandritis.Therapeutic strategies in the management of patients with chronic hepatitis B virus infection[J].The Lancet Infectious Diseases.2008(3)
  • 10Giovanni Raimondo,Jean-Pierre Allain,Maurizia R. Brunetto,Marie-Annick Buendia,Ding-Shinn Chen,Massimo Colombo,Antonio Craxì,Francesco Donato,Carlo Ferrari,Giovanni B. Gaeta,Wolfram H. Gerlich,Massimo Levrero,Stephen Locarnini,Thomas Michalak,Mario U. Mondelli,Jean-Michel Pawlotsky,Teresa Pollicino,Daniele Prati,Massimo Puoti,Didier Samuel,Daniel Shouval,Antonina Smedile,Giovanni Squadrito,Christian Trépo,Erica Villa,Hans Will,Alessandro R. Zanetti,Fabien Zoulim.Statements from the Taormina expert meeting on occult hepatitis B virus infection[J].Journal of Hepatology.2008(4)

共引文献25

同被引文献37

引证文献12

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部